Document Detail


Comparison of thymidine and folinic acid protection from methotrexate toxicity in human lymphoid cell lines.
MedLine Citation:
PMID:  6982753     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Hypoxanthine, thymidine, and folinic acid protection from methotrexate cytotoxicity were compared in human lymphoid cell lines variably sensitive to thymidine-induced growth suppression. Hypoxanthine protection differed among the cell lines, and the dose-response relationship for protection occurred within the physiologic bone marrow hypoxanthine concentration range. The slopes of the thymidine protection curves were virtually superimposable in a B cell line versus a T cell line, but threefold to fourfold higher thymidine concentrations were required to maximally protect the B versus the T cell line. Thymidine (plus hypoxanthine) protection was superior to that of folinic acid in both the B and the T cell lines when protection was delayed. As the interval between methotrexate and folinic acid exposure was progressively delayed, there was a linear decline in the degree of maximum protection in both cell lines. However, as thymidine exposure was progressively delayed, maximal protection was maintained, except at 12 hours in the B cell line. The influence of methotrexate on thymidine-induced growth suppression was studied. Methotrexate enhanced thymidine-induced growth suppression in sensitive cells as manifested by a significant shift of the dose-response curve. Deoxycytidine protection from thymidine toxicity was superior in the presence of methotrexate. The results of these studies indicate that thymidine protection and folinic acid protection against methotrexate toxicity produce different effects, which in part are dependent on the cell type. The complexity of these interactions points out the need for further studies.
Authors:
G P Browman
Related Documents :
1751763 - Karyological approach to the identification of true cell lines susceptible to the human...
2981613 - Anti-transferrin receptor antibody linked to pseudomonas exotoxin as a model immunotoxi...
12072403 - Igf-binding protein-3-induced growth inhibition and apoptosis do not require cell surfa...
Publication Detail:
Type:  Comparative Study; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Cancer treatment reports     Volume:  66     ISSN:  0361-5960     ISO Abbreviation:  Cancer Treat Rep     Publication Date:  1982 Dec 
Date Detail:
Created Date:  1983-01-27     Completed Date:  1983-01-27     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  7607107     Medline TA:  Cancer Treat Rep     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  2051-9     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
B-Lymphocytes / drug effects
Cell Division / drug effects
Cell Line
Dose-Response Relationship, Drug
Humans
Hypoxanthines / pharmacology
Leucovorin / pharmacology*
Lymphocytes / drug effects*
Methotrexate / toxicity*
T-Lymphocytes / drug effects
Thymidine / pharmacology*
Chemical
Reg. No./Substance:
0/Hypoxanthines; 50-89-5/Thymidine; 58-05-9/Leucovorin; 59-05-2/Methotrexate

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Massive vincristine overdose: failure of leucovorin to reduce toxicity.
Next Document:  Aneurysm of a saphenous vein bypass graft associated with aneurysms of native coronary arteries.